Morphic Therapeutic has completed a $80 million Series B financing to fund the biotechnology company’s two lead programs through clinical proof of concept, and to advance multiple other programs into the clinic.
Vertex Pharmaceuticals Incorporated and Genomics plc announced a three-year collaboration (extendable to five years) to use human genetics and machine learning to improve discovery of targets for precision medicines, and to advance understanding of the clinical impact of human genetic variation and patient stratification in diseases with significant unmet need.
Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium – consisting of Imperial College London and the Universities of Oxford and Edinburgh – Imperial Innovations, and Oxford BioMedica announced a global collaboration to develop a first-in-class, long-term therapy for patients with cystic fibrosis.
Reaction Biology Corporation, a leading contract research organization providing early-stage drug discovery services, announced that it has launched a new division to provide ion-channel discovery services.
Adimab will use its proprietary platform to discover and optimize antibodies against targets chosen by BI, who will have the rights to develop and commercialize therapeutic programs resulting from the collaboration.
Takeda Pharmaceutical announced a collaboration to help transform novel Stanford University research into next-generation treatments for diseases.
Zymeworks and GSK Enter Second Strategic Collaboration to Develop and Commercialize Bi-Specific Antibodies VANCOUVER, British Columbia–(BUSINESS WIRE)–Zymeworks Inc., a leader in the development of bi-specific and multi-specific antibodies and […]
Boehringer Ingelheim Will Invest 11 Billion Euros in Research and Development in the Next Five Years to Accelerate the Discovery of Next Generation Medical Breakthroughs
Biomedical, Cardimetabolic, Central Nervous System, Drug Discovery, Immunology, Innovation, Irritable Bowel Syndrome, Oncology, Partnership, Partnerships, R&D, Respiratory, Start-Ups, Start-ups, Startups11 billion euro R&D programme through 2020, with 5 billion euro dedicated to pre-clinical R&D and 1.5 billion euro planned for cooperation with external partners New partnerships with the […]
The U.S. biotechnology arena is undergoing a record-breaking M&A cycle for the industry. After generating M&A activity valued at $235 billion during 2014, the U.S. biotech sector produced more than $100 billion in deals during first-quarter 2015.
